In case some of you were waiting for Apothecury’s take on the Glivec judgement, I was waiting for this piece that I did for the Sunday Economic Times to be published. In a nutshell, in the article I explain why, as far as India’s generics industry is concerned, the Glivec outcome is not really a new win but more like savouring the same victory twice over. You can read the piece here. (Please ignore the New Delhi dateline in the story, I still operate from Mumbai).
Pic courtesy photostream of 757Live on Flickr.